It's a big day for people living with Migraine disease. For the first time in history, we have a treatment that was specifically developed to prevent Migraine attacks. Aimovig™ (erenumab-aooe) received FDA approval for the prevention of Migraine in patients experiencing four or more Migraine days per month.
GammaCore is now FDA-approved to treat migraine attacks. Gammacore is is a non-invasive vagus nerve stimulator. It's a hand-held device about the size of a cell phone that can be carried in a purse or backpack. Imagine putting a stop your next migraine attack with the push of a button. That dream is now possible.
Advances in delivery methods have made SPG blocks a more comfortable treatment option for intractable Migraine and Cluster Headache. SPG is a cluster of nerve fibers located inside the skull, behind the nose. It has connections to the trigeminal nerve and brain stem, which are both involved in Migraine and Cluster Headache attacks.
The SpringTMS device from eNeura was approved by the FDA for the acute treatment of Migraine with Aura on May 23, 2014. On September 7, 2017, it received FDA approval for the preventive treatment of Migraine, making it the only device with FDA approval for both acute and preventive treatment.
One of the wisest and most useful tasks we can undertake is maintaining a comprehensive Migraine and Headache diary. Not only can a well maintained Migraine and Headache diary help us identify our triggers, it can help us track the effectiveness of medications and any patterns to our Migraines and Headaches.